$ANCN is on fire today! we get a +184% gain on the news of last week that its first patient has been enrolled in a clinical trial for a treatment aimed at “liver, skin, and lung fibrosis-related diseases such as PSC and systemic sclerosis .”
Here is the link of the press release.
With his announcement signals the company’s on the right track with gaining approval with the U.S. Food and Drug Administration for this treatment.
There is currently, no disease-modifying drugs have been approved by the FDA for these disorders.
The question is WHY is the news pick up one week later?
Here is the graph of the day.
Here is the 30 day overview.